Syneris Weekly Briefing
Global Regulatory Intelligence Review
Medical devices · IVDs · SaMD | Published 9 Nov 2026 · Review window 30 Oct – 9 Nov 2026
Top stories this week
About this edition
Every development in this edition has been confirmed against the issuing regulator's own publication, and links go directly to those primary sources.
- Action required — the change is likely to require regulatory or compliance action, such as a registration, submission, notified-body application or QMS update.
- Review — the change may be relevant and should be assessed by regulatory affairs for applicability to specific products or markets.
- Informational — useful intelligence; no immediate action identified.
Status: NEW / REVISED / PROPOSED / UPCOMING / CLARIFICATION. Impact ratings are a general guide; applicability depends on your products and markets.
This week at a glance
Significant new developments
FDA finalises its emerging-pathogen IVD validation guidance
FDA has issued the final version of "Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency", dated November 2026, replacing the January 2025 draft under docket FDA-2024-D-2707 (FDA). The notice of availability is scheduled for the 10 November Federal Register (Federal Register).
The guidance and its template set out the validation data FDA expects in a pre-EUA, an EUA request, or for a test offered under an emergency enforcement-discretion policy. Developers that keep emergency-response assay platforms should compare their preparedness protocols with the final template.
↑ Back to this week at a glanceAI-assisted cervical cytology gets its own Class II regulation
A final order published on 5 November codifies 21 CFR 864.3900, the digital cervical cytology slide imaging system with an AI algorithm, in Class II with special controls (Federal Register). The device is a prescription IVD that selects and presents areas of interest on digital images of Pap test slides to help the reader reach a cytology diagnosis. The classification has applied since the De Novo grant on 31 January 2024.
Developers of cervical-screening software and image-based tests can now use this device type as a predicate, and should map the special controls, including labeling under 21 CFR 809.10(b), against their submissions.
↑ Back to this week at a glanceSouth Korea tightens its device cybersecurity review criteria
MFDS revised its cybersecurity approval and review guideline for medical devices on 30 October (guideline 0995-06) (MFDS). The revision changes requirement items on changing authentication information, password strength set according to product characteristics, input-validation checks and evidence for error handling.
MFDS briefed industry on 28 October and will run online training on 26 November (MFDS press release). Manufacturers of connected devices and software registered in Korea should check their cybersecurity files against the revised items.
↑ Back to this week at a glanceChina: new GMP inspection guidelines for IVD reagents and other high-risk devices
NMPA notice 国药监械管〔2026〕16号 issues revised GMP inspection guidelines for sterile devices, implantable devices, IVD reagents and custom dentures. They have applied since 1 November 2026 and replace the 2015 and 2016 on-site inspection guidelines; licensing and post-market inspections are now judged against them (CFDI, reposting the NMPA notice).
They sit alongside the revised device GMP and general inspection guideline, also in force from 1 November (NMPA). Companies with IVD or sterile production sites in China, including contract manufacturers, should check their sites against the new IVD and sterile texts.
↑ Back to this week at a glanceEU guidance on clinical evidence for orphan IVDs
The MDCG has published MDCG 2026-6 on clinical evidence for orphan IVDs, meaning tests for conditions affecting no more than 12,000 people a year in the EU (European Commission). It explains when limited clinical performance data can be justified and how expert panels are involved. Manufacturers of rare-disease IVDs should read it before planning their IVDR performance evaluation.
↑ Back to this week at a glanceUpdates to existing requirements
Canada revises its List of Recognized Standards
Health Canada's revised list took effect on 2 November 2026 (Health Canada). New entries include CLSI EP35 on specimen-type equivalence for IVDs, IEC 80601-2-26, -2-49 and -2-77, ISO 17665 and ISO 18562-1 and -2. CLSI MM12 and MM16, IEC 60601-2-26 and -2-49, ISO 17665-1 and ISO 8359 are among the standards removed, and recognition of CLSI EP25, IEC 60601-2-24 and ISO 10993-1 has been updated.
No transition period is stated. Manufacturers citing removed or superseded editions in Canadian declarations of conformity should update them.
↑ Back to this week at a glancePMDA platform still offline
PMDA's notice on the suspension of its Medical Device Web Application Platform was posted on 29 October; the service is still suspended and no restart date has been set (PMDA). Applications and notifications should continue to go through MHLW's FD application software, and PMDA has yet to announce how documents in pending files can be replaced.
↑ Back to this week at a glanceUS: three more De Novo classifications
Final orders published on 5 and 6 November create device types for prognostic assessment software for mild cognitive impairment (21 CFR 882.1454), a wearable vibration device for orthopedic use (21 CFR 888.5895) and an external mechanical stimulator for ear, nose and throat use (21 CFR 874.6010). None are IVDs.
↑ Back to this week at a glanceUS: final guidance on hepatitis B testing of blood donations
CBER's final guidance on reducing the risk of transfusion-transmitted hepatitis B was announced on 3 November (Federal Register; FDA). Blood establishments that test with HBV nucleic acid tests and anti-HBc no longer need to test for HBsAg, but Source Plasma testing stays as it is. Makers of blood-screening assays should expect demand to shift.
↑ Back to this week at a glanceOn the horizon
FDA asks for views on autonomous and remotely operated robotic devices
CDRH has published a discussion paper on benefit-risk for robotic devices with autonomous or remote teleoperation capabilities, with comments due by 5 January 2027 under docket FDA-2026-N-13135 (FDA). A public workshop follows on 2–3 December (FDA workshop).
↑ Back to this week at a glanceChina consults on device vigilance in hospitals
NMPA's Center for Drug Reevaluation has released a draft guide on medical device vigilance work in medical institutions, with comments due by 25 November (CDR). It covers the user-facility side of vigilance and adds nothing new for manufacturers yet.
↑ Back to this week at a glanceClarifications worth noting
EU — EUDAMED registration. Devices already on the market must be registered in EUDAMED by 28 November 2026 (Commission timeline).
Canada — MDEL Phase 2 and inspections from 1 December. The MDEL Phase 2 amendments, the online FRM-0292 and the new GUI-0016 take effect on 1 December 2026 (Health Canada bulletin). A revised version of GUI-0064, which describes how Health Canada inspects medical device establishments, takes effect the same day and replaces version 7 (GUI-0064).
US — QMSR FAQ. FDA's QMSR FAQ page was updated on 5 November with a new contact address (AskOICE@fda.hhs.gov); the policy is unchanged (FDA).
Japan — PMDA and AI. PMDA has published early basic principles for its own use of AI in regulatory work. They set no new requirements for products (PMDA).
Standards changes
Canada — recognized standards. The revised List of Recognized Standards took effect on 2 November 2026; see the item above (Health Canada).
EU — Battery Regulation. Delegated Regulation (EU) 2026/1770 applies from 11 November 2026 and keeps the derogation for IVDs (EUR-Lex). No new MDR/IVDR harmonised-standards decision and no new FDA recognized-standards list were published this week.
Upcoming implementation deadlines
Next 30 days (9 Nov – 9 Dec 2026)
| Date | Jurisdiction | Item | Scope | Impact |
|---|---|---|---|---|
| 10 Nov 2026 | Switzerland | swissdamed webinar | MD + IVD | Info |
| 11 Nov 2026 | EU | Delegated Reg. (EU) 2026/1770 applies (batteries; IVD derogation) | MD + IVD | Info |
| 16 Nov 2026 | South Korea | Comments close: MFDS IVD regulation amendment (MFDS) | IVD | Review |
| 17 Nov 2026 | US | Comments close: PMA eSTAR draft guidance | MD + IVD | Info |
| 19 Nov 2026 | US | Microbiology Devices Panel (pathogen-agnostic sequencing) | IVD | Review |
| 23 Nov 2026 | US | Comments close: ASCA information collection | MD + IVD | Info |
| 24 Nov 2026 | US | Comments close: RASD draft guidance | MD | Review |
| 25 Nov 2026 | China | Comments close: draft hospital vigilance guide | MD + IVD | Info |
| 26 Nov 2026 | South Korea | MFDS online training on the revised cybersecurity guideline | MD / SaMD | Info |
| 28 Nov 2026 | EU | EUDAMED registration of devices already on the market | MD + IVD | Action required |
| 30 Nov 2026 | US | Comments close: CDRH FY2027 guidance lists | MD + IVD | Info |
| 1 Dec 2026 | Canada | MDEL Phase 2 in force; online FRM-0292, GUI-0016 and GUI-0064 effective | MD + IVD | Action required |
| 2–3 Dec 2026 | US | FDA workshop on robotic devices with autonomy or teleoperation | MD | Info |
| 3 Dec 2026 | IMDRF | N52 Ed.3 labeling consultation closes (IMDRF) | MD + IVD | Review |
Next 90 days (to 7 Feb 2027)
| Date | Jurisdiction | Item | Scope | Impact |
|---|---|---|---|---|
| 10 Dec 2026 | South Korea | Medical Devices Act amendment (Act 21775) in force | MD | Review |
| 11 Dec 2026 | Brazil | Sandbox CP 1.427/2026 closes | Horizontal | Info |
| 14 Dec 2026 | EU | Indicative plenary date, MDR/IVDR revision (OEIL) | MD + IVD | Review |
| Dec 2026 | EU | SSCP/SSP upload opens in EUDAMED (planned) | MD + IVD | Review |
| Dec 2026 | UK | MHRA draft PCCP guidance planned | SaMD/AI | Review |
| 22 Dec 2026 | US | Comments close: product jurisdiction / export certificate information collections | MD + IVD | Info |
| 26 Dec 2026 | US | COVID-19 device EUAs end, including SARS-CoV-2 tests | IVD | Action required |
| 28 Dec 2026 | US | Comments close: IDE eSTAR draft guidance | MD + IVD | Review |
| 31 Dec 2026 | Switzerland | End of swissdamed device registration transition | MD + IVD | Review |
| 31 Dec 2026 | Singapore | HSA Registration Support Initiative window ends | MD + IVD | Info |
| 5 Jan 2027 | US | Comments close: robotic devices discussion paper | MD | Info |
| 28 Jan 2027 | US | Comments close: essential drug delivery draft guidance | MD | Review |
| 28 Jan 2027 | Brazil | CP 1.420–1.423/2026 close | MD | Info |
Next 180 days (to 8 May 2027)
| Date | Jurisdiction | Item | Scope | Impact |
|---|---|---|---|---|
| 25 Feb 2027 | EU | Implementing Reg. (EU) 2026/977 notified-body maximum timelines apply (EUR-Lex) | MD + IVD | Review |
| 17 Mar 2027 | Japan | Comments close: PMDA generative AI review points | SaMD/AI | Review |
| 27 Mar 2027 | EU | SSCP/SSP upload for devices already on the market (MDCG 2026-4 rev.1) | MD + IVD | Review |
Next 365 days (to 9 Nov 2027)
| Date | Jurisdiction | Item | Scope | Impact |
|---|---|---|---|---|
| 20 May 2027 | Japan | PMD Act amendments in force, including IVD performance re-evaluation and reporting | IVD | Review |
| 26 May 2027 | EU | IVDR legacy Class B / sterile Class A: notified-body application deadline; UDI carrier required on Class A IVD labels | IVD | Action required |
| 17 Jun 2027 | Canada | GUI-0137 v4 shortage reporting guidance effective | MD + IVD | Review |
| 26 Sep 2027 | EU | IVDR legacy Class B / sterile Class A: notified-body written agreement deadline | IVD | Action required |
EU IVDR transition dates: EUR-Lex – Regulation (EU) 2024/1860; IVDR UDI dates: EUR-Lex – Regulation (EU) 2017/746, Art. 113.
About this briefing
Compiled from primary regulatory sources (national authorities, official legislation and gazettes, European Commission, MDCG, FDA and the Federal Register). Secondary sources are used only for discovery; developments that could not be confirmed from a primary source are not published. Requirements in one jurisdiction should not be assumed to apply in another. This briefing is for information only and is not legal or regulatory advice; confirm applicability with your regulatory affairs team before acting.